1. Home
  2. AUPH vs PLSE Comparison

AUPH vs PLSE Comparison

Compare AUPH & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • PLSE
  • Stock Information
  • Founded
  • AUPH 1993
  • PLSE 2014
  • Country
  • AUPH Canada
  • PLSE United States
  • Employees
  • AUPH N/A
  • PLSE N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • PLSE Medical/Dental Instruments
  • Sector
  • AUPH Health Care
  • PLSE Health Care
  • Exchange
  • AUPH Nasdaq
  • PLSE Nasdaq
  • Market Cap
  • AUPH 1.1B
  • PLSE 1.1B
  • IPO Year
  • AUPH 1999
  • PLSE 2016
  • Fundamental
  • Price
  • AUPH $8.77
  • PLSE $15.09
  • Analyst Decision
  • AUPH Strong Buy
  • PLSE
  • Analyst Count
  • AUPH 2
  • PLSE 0
  • Target Price
  • AUPH $11.50
  • PLSE N/A
  • AVG Volume (30 Days)
  • AUPH 1.4M
  • PLSE 182.5K
  • Earning Date
  • AUPH 07-31-2025
  • PLSE 08-11-2025
  • Dividend Yield
  • AUPH N/A
  • PLSE N/A
  • EPS Growth
  • AUPH N/A
  • PLSE N/A
  • EPS
  • AUPH 0.27
  • PLSE N/A
  • Revenue
  • AUPH $247,295,000.00
  • PLSE N/A
  • Revenue This Year
  • AUPH $12.15
  • PLSE N/A
  • Revenue Next Year
  • AUPH $18.31
  • PLSE N/A
  • P/E Ratio
  • AUPH $31.76
  • PLSE N/A
  • Revenue Growth
  • AUPH 29.20
  • PLSE N/A
  • 52 Week Low
  • AUPH $5.20
  • PLSE $10.52
  • 52 Week High
  • AUPH $10.67
  • PLSE $25.00
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 66.00
  • PLSE 38.06
  • Support Level
  • AUPH $7.71
  • PLSE $14.76
  • Resistance Level
  • AUPH $8.29
  • PLSE $15.61
  • Average True Range (ATR)
  • AUPH 0.25
  • PLSE 0.72
  • MACD
  • AUPH 0.03
  • PLSE -0.09
  • Stochastic Oscillator
  • AUPH 84.40
  • PLSE 16.05

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

Share on Social Networks: